
Victoria N Parikh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4855755/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. Circulation, 2012, 125, 1520-1532.	1.6	246
2	Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2020, 13, e000067.	3.6	200
3	Regional Variation in <i>RBM20</i> Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	3.9	96
4	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
5	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	2.2	43
6	Next-Generation Sequencing in Cardiovascular Disease. Circulation, 2017, 135, 406-409.	1.6	33
7	Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation, 2020, 142, 1605-1608.	1.6	33
8	Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H348-H356.	3.2	28
9	Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation, 2019, 140, 765-778.	1.6	26
10	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 2019, 10, 2760.	12.8	22
11	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	1.7	19
12	Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. Frontiers in Physiology, 2020, 11, 181.	2.8	18
13	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	2.4	13
14	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 236-241.	2.1	12
15	Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease. Circulation Genomic and Precision Medicine, 2021, 14, e002964.	3.6	10
16	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	7.1	7
17	Wrestling the Giant. Circulation: Cardiovascular Genetics, 2016, 9, 392-394.	5.1	3
18	Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications. Current Cardiovascular Risk Reports, 2021, 15, 1.	2.0	2

VICTORIA N PARIKH

#	Article	IF	CITATIONS
19	Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity. Journal of Cardiac Failure, 2021, 27, 822-824.	1.7	2
20	Pathological Overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis. Circulation Genomic and Precision Medicine, 2019, 12, 452-454.	3.6	1
21	Circulating microRNAs as Biomarkers for Sudden Cardiac Death. JACC: Clinical Electrophysiology, 2020, 6, 80-82.	3.2	1
22	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation Genomic and Precision Medicine, 0, , .	3.6	0